Patents by Inventor Frank Pedi, Jr.
Frank Pedi, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090068269Abstract: Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains a plurality of substrates including the opioid analgesic in sustained release form. The substrates have a diameter from about 0.1 mm to about 3 mm.Type: ApplicationFiled: September 10, 2008Publication date: March 12, 2009Applicant: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Mark Chasin, Frank Pedi, JR.
-
Patent number: 7316821Abstract: A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing the coated substrate at a temperature and relative humidity elevated to a suitable level above ambient conditions until the coated dosage form attains a stabilized dissolution profile substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.Type: GrantFiled: June 18, 2004Date of Patent: January 8, 2008Assignee: Purdue Pharma, L.P.Inventors: Benjamin Oshlack, Mark Chasin, Frank Pedi, Jr.
-
Patent number: 7070806Abstract: A stable solid controlled release formulation having a coating derived from an aqueous dispersion of a hydrophobic acrylic polymer includes a substrate including an active agent selected from the group consisting of a systemically active therapeutic agent, a locally active therapeutic agent, a disinfecting and sanitizing agent, a cleansing agent, a fragrance agent and a fertilizing agent, overcoated with an aqueous dispersion of the plasticized water-insoluble acrylic polymer. The formulation provides a stable dissolution of the active agent which is unchanged after exposure to accelerated storage conditions.Type: GrantFiled: October 17, 2002Date of Patent: July 4, 2006Assignee: Purdue Pharma LPInventors: Benjamin Oshlack, Mark Chasin, Frank Pedi, Jr.
-
Patent number: 7060293Abstract: An oral dosage form of morphine is formulated by powder-layering an homogeneous mixture of morphine sulfate and hydrous lactose impalpable onto inert beads to obtain a multiparticulate product. A plurality of the powder-layered beads may be administered either in immediate release form or in an extended release form by coating with a hydrophobic material. In addition, multi-particulate oral dosage forms containing therapeutically effective agents containing a plurality of pharmaceutically acceptable inert beads powder-layered with homogeneous mixture of a therapeutically effective agent and hydrous lactose impalpable are also disclosed. A method of preparing the dosage forms as well as a method preparing spheroids containing the homogeneous mixture of therapeutically effective agent and hydrous lactose impalpable are also disclosed.Type: GrantFiled: June 20, 2000Date of Patent: June 13, 2006Assignee: Purdue PharmaInventors: Benjamin Oshlack, Frank Pedi, Jr.
-
Patent number: 6905709Abstract: A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing the coated substrate at a temperature and relative humidity elevated to a suitable level above ambient conditions until the coated dosage form attains a stabilized dissolution profile substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.Type: GrantFiled: November 12, 2001Date of Patent: June 14, 2005Assignee: Purdue Pharma, LPInventors: Benjamin Oshlack, Mark Chasin, Frank Pedi, Jr.
-
Patent number: 6316031Abstract: A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing the coated substrate at a temperature and relative humidity elevated to a suitable level above ambient conditions until the coated dosage form attains a stabilized dissolution profile substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.Type: GrantFiled: December 22, 1999Date of Patent: November 13, 2001Assignee: Purdue Pharma LPInventors: Benjamin Oshlack, Frank Pedi, Jr., Mark Chasin
-
Patent number: 6143353Abstract: A stable solid controlled release formulation having a coating derived from an aqueous dispersion of a hydrophobic acrylic polymer includes a substrate including an active agent selected from the group consisting of a systemically active therapeutic agent, a locally active therapeutic agent, a disinfecting and sanitizing agent, a cleansing agent, a fragrance agent and a fertilizing agent, overcoated with an aqueous dispersion of the plasticized water-insoluble acrylic polymer. The formulation provides a stable dissolution of the active agent which is unchanged after exposure to accelerated storage conditions.Type: GrantFiled: March 11, 1997Date of Patent: November 7, 2000Assignee: Purdue Pharma LPInventors: Benjamin Oshlack, Mark Chasin, Frank Pedi, Jr.
-
Patent number: 6129933Abstract: A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing the coated substrate at a temperature and relative humidity elevated to a suitable level above ambient conditions until the coated dosage form attains a stabilized dissolution profile substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.Type: GrantFiled: July 24, 1997Date of Patent: October 10, 2000Assignee: Purdue Pharma LPInventors: Benjamin Oshlack, Mark Chasin, Frank Pedi, Jr.
-
Patent number: 6103261Abstract: Solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method of 100 rpm in 900 ml aqueous buffer at 37.degree. C. from about 12.5% to about 42.5% (by weight) active agent released after 1 hour, from about 25% to about 55% (by weight) active agent released after 2 hours, from about 45% to about 75% (by weight) opioid analgesic released after 4 hours and greater than about 60% (by weight) opioid analgesic released after a hours, the in-vitro release rate being substantially independent of pH and chosen such that the peak plasma level of active agent obtained in-vivo between about 2 and about 8 hours after administration of the dosage form.Type: GrantFiled: January 6, 1999Date of Patent: August 15, 2000Assignee: Purdue Pharma LPInventors: Mark Chasin, Benjamin Oshlack, Frank Pedi, Jr.
-
Patent number: 5958459Abstract: Solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method of 100 rpm in 900 ml aqueous buffer at 37.degree. C. from about 12.5% to about 42.5% (by weight) active agent released after 1 hour, from about 25% to about 55% (by weight) active agent released after 2 hours, from about 45% to about 75% (by weight) opioid analgesic released after 4 hours and greater than about 60% (by weight) opioid analgesic released after 8 hours, the in-vitro release rate being substantially independent of pH and chosen such that the peak plasma level of active agent obtained in-vivo between about 2 and about 8 hours after administration of the dosage form.Type: GrantFiled: November 27, 1995Date of Patent: September 28, 1999Assignee: Purdue Pharma L.P.Inventors: Mark Chasin, Benjamin Oshlack, Frank Pedi, Jr.
-
Patent number: 5681585Abstract: A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing the coated substrate at a temperature and relative humidity elevated to a suitable level above ambient conditions until the coated dosage form attains a stabilized dissolution profile substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.Type: GrantFiled: June 20, 1996Date of Patent: October 28, 1997Assignee: Euro-Celtique, S.A.Inventors: Benjamin Oshlack, Mark Chasin, Frank Pedi, Jr.
-
Patent number: 5639476Abstract: A stable solid controlled release formulation having a coating derived from an aqueous dispersion of a hydrophobic acrylic polymer includes a substrate including an active agent selected from the group consisting of a systemically active therapeutic agent, a locally active therapeutic agent, a disinfecting and sanitizing agent, a cleansing agent, a fragrance agent and a fertilizing agent, overcoated with an aqueous dispersion of the plasticized water-insoluble acrylic polymer. The formulation provides a stable dissolution of the active agent which is unchanged after exposure to accelerated storage conditions.Type: GrantFiled: June 2, 1995Date of Patent: June 17, 1997Assignee: Euro-Celtique, S.A.Inventors: Benjamin Oshlack, Mark Chasin, Frank Pedi, Jr.
-
Patent number: 5580578Abstract: A stable solid controlled release formulation having a coating derived from an aqueous dispersion of a hydrophobic acrylic polymer includes a substrate including an active agent selected from the group consisting of a systemically active therapeutic agent, a locally active therapeutic agent, a disinfecting and sanitizing agent, a cleansing agent, a fragrance agent and a fertilizing agent, overcoated with an aqueous dispersion of the plasticized water-insoluble acrylic polymer. The formulation provides a stable dissolution of the active agent which is unchanged after exposure to accelerated storage conditions.Type: GrantFiled: July 27, 1993Date of Patent: December 3, 1996Assignee: Euro-Celtique, S.A.Inventors: Benjamin Oshlack, Frank Pedi, Jr., Mark Chasin
-
Patent number: 5472712Abstract: A stabilized solid controlled release formulation having a coating derived from an aqueous dispersion of a hydrophobic polymer is obtained by overcoating a substrate including an active agent selected from the group consisting of a systemically active therapeutic agent, a locally active therapeutic agent, a disinfecting and sanitizing agent, a cleansing agent, a fragrance agent and a fertilizing agent, with an aqueous dispersion of the plasticized hydrophobic polymer and then curing the coated substrate at a temperature above the glass transition temperature of the plasticized hydrophobic polymer, until a curing endpoint is reached at which the coated substrate provides a stabilized dissolution of the active agent which is unchanged after exposure to accelerated storage conditions, the endpoint being determined by comparing the dissolution profile of the formulation immediately after curing to the dissolution profile of the formulation after exposure to accelerated storage conditions of at least one month atType: GrantFiled: June 23, 1993Date of Patent: December 5, 1995Assignee: Euroceltique, S.A.Inventors: Benjamin Oshlack, Mark Chasin, Frank Pedi, Jr.
-
Patent number: 5411745Abstract: An oral dosage form of morphine is formulated by powder-layering an homogeneous mixture of morphine sulfate and hydrous lactose impalpable onto inert beads to obtain a multiparticulate product. A plurality of the powder-layered beads may be administered either in immediate release form or in an extended release form by coating with a hydrophobic material.Type: GrantFiled: May 25, 1994Date of Patent: May 2, 1995Assignee: Euro-Celtique, S.A.Inventors: Benjamin Oshlack, Frank Pedi, Jr.
-
Patent number: 5286493Abstract: A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of an acrylic polymer is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of the plasticized acrylic polymer and then curing the coated substrate at a temperature above the glass transition temperature of the plasticized acrylic polymer, until the coated dosage form attains a stabilized dissolution profile substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.Type: GrantFiled: January 27, 1992Date of Patent: February 15, 1994Assignee: Euroceltique, S.A.Inventors: Benjamin Oshlack, Mark Chasin, Frank Pedi, Jr.
-
Patent number: 5273760Abstract: A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active agent with an aqueous dispersion of ethylcellulose and then curing the coated substrate at a temperature and relative humidity elevated to a suitable level above ambient conditions until the coated dosage form attains a stabilized dissolution profile substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.Type: GrantFiled: December 24, 1991Date of Patent: December 28, 1993Assignee: Euroceltigue, S.A.Inventors: Benjamin Oshlack, Frank Pedi, Jr., Mark Chasin
-
Patent number: 4996048Abstract: Minimizing the leaching of iodine through packaging containing organic iodophor solution, by introducing into the packaging an amount of additional iodide which minimizes leaching of the iodine through the packaging and stabilizes the iodophor solution therein. The iodophor is preferably polyvinylpyrrolidone iodine.Type: GrantFiled: November 30, 1988Date of Patent: February 26, 1991Assignee: Euroceltique, S.A.Inventors: Dileep Bhagwat, Oliver Iny, Frank Pedi, Jr.